For you to figure out applicability to your next stroke. Hope you are conscious in the emergency room.
High On-Treatment Platelet Reactivity in Danish Hyper-Acute Ischaemic Stroke Patients
- 1Department of Neurology, Neurovascular Centre, Zealand University Hospital, Roskilde, Denmark
- 2Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- 3OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
- 4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Objective: Early anti-platelet therapy
is a cornerstone in the prevention of recurrent ischaemic stroke (IS)
and transient ischaemic attacks (TIAs), although the responsiveness to
anti-platelet medications varies among patients. Several studies have
reported that patients with ischaemic stroke who exhibit high
on-treatment platelet reactivity (HTPR) 5–10 days after antiplatelet
medication onset, have an increased risk of vascular events. In this
study we aim to determine the prevalence of HTPR in the hyper-acute
stroke phase less than 48 h from symptom onset, after the administration
of a 300 mg bolus of oral clopidogrel in a real-world setting in Danish
IS and TIA patients.
Material and Methods: In total, 219
Danish patients with acute IS or TIA received 300 mg of oral clopidogrel
on admission. Blood samples from all patients were analyzed using the
VerifyNow P2Y12 system at 8–24 h after clopidogrel intake. Concomitant
therapy and the intervals between ictus and blood collection,
clopidogrel intake and blood collection, and blood sampling and analysis
were recorded for all patients.
Results: HTPR in the hyper-acute stroke
phase was observed in 28.8% (63/219) samples. After adjustment for age,
sex, co-morbidities, and co-medications, none of the tested variables
exhibited an association with HTPR or the platelet reaction unit value
measured using the VerifyNow P2Y12 system.
Conclusions: The recognition of HTPR to
specific anti-platelet agents in the hyper-acute phase after stroke may
be the first step toward interventions that may further minimize the
early recurrent stroke risk. Further large randomized trials including
clinical outcome assessments are necessary.
Introduction
Anti-platelet therapy is a cornerstone in the prevention
of secondary ischaemic stroke (IS), and clopidogrel has been reported
to lower the long-term risk of recurrent stroke with the same efficiency
as acetylsalicylic acid combined with dipyridamole (1). Patients with a transient ischaemic attack (TIA) exhibit an increased stroke risk in the acute phase (2) although this risk is lowered after treatment with anti-platelet agents (3).
The importance of very early treatment in both acute IS and TIA has
been further established in a recent time-course analysis of existing
randomized trials (4).
However, the platelet function was not explored in these studies.
Although the prevalence of patients with IS who exhibit high on
treatment platelet reactivity (HTPR), also known as non-responders, has
been evaluated in several other studies, the results have been highly
variable (8–61%) (5).
Clopidogrel is an anti-platelet aggregation drug that
inhibits adenosine 5-diphosphate from binding to its P2Y12 receptor on
the surface of the platelet, resulting in the inhibition of platelet
reactivity. This pro-drug requires biotransformation (two-step
oxidation) that is catalyzed by several cytochrome P450 (CYP) enzymes. A
previous study recommended that platelet reactivity should be tested at
8 h after the administration of a loading dose of 300 mg (6).
In a recent meta-analysis, it was found that the
recurrent stroke or TIA risk was significantly higher in patients with
HTPR (RR = 1.81), and that the HTPR prevalence after clopidogrel
administration was 27% (7).
However, the studies included in this meta-analysis differed with
regard to the ethnicity of patients, treatment regimen, HTPR assessment
technique, and treatment period at the time of HTPR testing. And
importantly, the studies evaluated HTPR >3 days after treatment
start.
The aim of the present study was to establish the
prevalence of HTPR at 8–24 h after the intake of clopidogrel 300 mg in
the acute phase (lt;48 h after symptom onset) after IS or TIA in a
real-world setting.
No comments:
Post a Comment